Worth reading
66In focus
Scored from 3 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
7
Millions of yenWording
Conditional
How definitive the wording is.Details of issuance or disposal
Issuance of the 5th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) through a third-party allotment
Amount of funds to be raised
Proceeds from the issuance of the 5th Series of Stock Acquisition Rights: ¥0 million; proceeds from the exercise of the 5th Series of Stock Acquisition Rights: ¥382 million; estimated net proceeds: ¥368 million
Estimated issuance expenses
¥15 million
Specific use of funds
Research and development expensesAmount ¥80 million / Scheduled timing of expenditures September 2024 to March 2027
Personnel expenses at the development laboratory and sales activity expenses for developing sales channels in the Labo sales divisionAmount ¥80 million / Scheduled timing of expenditures September 2024 to March 2027
Cost of purchasing materials and raw materialsAmount ¥100 million / Scheduled timing of expenditures January 2026 to March 2027
Manufacturing costs and factory equipment renewal costs, etc.Amount ¥60 million / Scheduled timing of expenditures January 2026 to March 2027
Marketing expensesAmount ¥48 million / Scheduled timing of expenditures April 2026 to March 2027
Terms of the stock acquisition rights
Exercise price
The document states that the stock acquisition rights include an exercise price adjustment clause, but the initial exercise price and the floor for adjustments are Not disclosed
Most recent equity financing
6 August 2024: Issuance of the 5th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) through a third-party allotment. The amount was the initially expected ¥375 million stated in this document (estimated net proceeds of ¥361 million)
Impact on Business Performance
The Company believes that the change in the scheduled expenditure period will have a minor impact on results for the current fiscal year. If any matter requiring disclosure arises regarding the impact on future results, the Company will promptly make an announcement.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of the 5th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) through a third-party allotment |
| Amount of funds to be raised | Proceeds from the issuance of the 5th Series of Stock Acquisition Rights: ¥0 million; proceeds from the exercise of the 5th Series of Stock Acquisition Rights: ¥382 million; estimated net proceeds: ¥368 million |
| Estimated issuance expenses | ¥15 million |
| Specific use of funds | Details Research and development expenses / Amount ¥80 million / Scheduled timing of expenditures September 2024 to March 2027, Details Personnel expenses at the development laboratory and sales activity expenses for developing sales channels in the Labo sales division / Amount ¥80 million / Scheduled timing of expenditures September 2024 to March 2027, Details Cost of purchasing materials and raw materials / Amount ¥100 million / Scheduled timing of expenditures January 2026 to March 2027, Details Manufacturing costs and factory equipment renewal costs, etc. / Amount ¥60 million / Scheduled timing of expenditures January 2026 to March 2027, Details Marketing expenses / Amount ¥48 million / Scheduled timing of expenditures April 2026 to March 2027 |
| Exercise price | The document states that the stock acquisition rights include an exercise price adjustment clause, but the initial exercise price and the floor for adjustments are Not disclosed |
| Most recent equity financing | 6 August 2024: Issuance of the 5th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) through a third-party allotment. The amount was the initially expected ¥375 million stated in this document (estimated net proceeds of ¥361 million) |
| Impact on Business Performance | The Company believes that the change in the scheduled expenditure period will have a minor impact on results for the current fiscal year. If any matter requiring disclosure arises regarding the impact on future results, the Company will promptly make an announcement. |
Items this document does not state (21)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valuePayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Due to the impact of escalating tensions in the Middle East, the launch of the 50th anniversary commemorative product was changed from the third quarter to the fourth quarter of the fiscal year ending March 2027, and much of the manufacturing schedule was moved to after September 2026. The marketing period was also changed to the fourth quarter of the fiscal year ending March 2027.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.